(Q83970218)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

T Matsumoto

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

M Shiraki

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

H Hagino

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

H Iinuma

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

T Nakamura

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

9 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

Osteoporosis International

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1532-1538

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

Development of a highly sensitive and specific two-site enzyme immunoassay for parathyroid hormone (1-34): application to pharmacokinetic study on intranasal parathyroid hormone (1-34) in human

29 January 2020

cites work

1 reference

12 December 2020

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

12 December 2020

Diagnostic criteria for primary osteoporosis: year 2000 revision

1 reference

12 December 2020

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

10.1007/S00198-006-0159-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16767525%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference